Current Report Filing (8-k)
04 Juni 2020 - 10:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May
29, 2020
SONOMA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-33216
|
|
68-0423298
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
1129 N. McDowell Blvd.
Petaluma, CA 94954
(Address of principal executive offices)
(Zip Code)
(707) 283-0550
(Registrant’s telephone number, including
area code)
Not applicable.
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common stock
|
SNOA
|
The Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth
company o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02
|
|
Departure of Directors of Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
As
previously announced, at the beginning of 2019 we began to carefully evaluate our business with the goal of achieving and sustaining
profitability. As part of this process, we are consolidating most of our corporate functions in our offices in Woodstock, Georgia.
In May, we closed our offices in the Seattle, Washington area. As part of this consolidation, on May 29, 2020, Dr. Robert
Northey was released as our Executive Vice President of Research and Development. Dr. Northey has agreed to stay on as a consultant
to provide continuity in our research and development activities. Dr. Northey has been a critical contributor to many of our product
development activities and we thank him for all of his services over the last 17 years. We look forward to ongoing collaboration.
In connection
with Dr. Northey’s termination we entered into a separation and release agreement. Pursuant to the agreement Dr. Northey
will receive $204,000 in cash as a separation payment plus $26,600 for accrued paid time off. We will continue to reimburse Dr.
Northey for his health care expenses for him and his dependents for twelve months should he so elect. All outstanding time-based
equity-based compensation awards granted to Dr. Northey during his employment shall become fully vested and remain exercisable
for the remainder of their full term.
On May 30, 2020,
we entered into a consulting agreement with Dr. Robert Northey. Pursuant to the terms of the agreement, Dr. Northey will provide
consulting and advisory services in order to assist with the transition to a new research and development department. We will pay
Dr. Northey a fee of $200 per hour.
This report contains
forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions,
beliefs, expectations, strategies, predictions or any other statements related to our future activities or future events or conditions. These
statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made
by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions
that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted
in the forward-looking statements due to numerous factors, including those risks discussed in our Annual Report on Form 10-K
and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date
on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances
after the date of this report, except as required by law.
Item 9.01 Financial
Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Sonoma Pharmaceuticals, Inc.
|
|
(Registrant)
|
|
|
Date: June 4, 2020
|
By:
|
/s/ Amy Trombly
|
|
Name:
Title:
|
Amy Trombly
Chief Executive Officer
|
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024